Compare VIR & PLSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VIR | PLSE |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2019 | 2015 |
| Metric | VIR | PLSE |
|---|---|---|
| Price | $9.06 | $23.04 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 1 |
| Target Price | $19.63 | ★ $22.00 |
| AVG Volume (30 Days) | ★ 2.3M | 225.8K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 17.49 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $68,556,000.00 | N/A |
| Revenue This Year | N/A | $840.00 |
| Revenue Next Year | $1,049.62 | $287.54 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.16 | $12.56 |
| 52 Week High | $10.91 | $26.30 |
| Indicator | VIR | PLSE |
|---|---|---|
| Relative Strength Index (RSI) | 52.52 | 60.50 |
| Support Level | $8.67 | $13.75 |
| Resistance Level | $10.29 | $23.18 |
| Average True Range (ATR) | 0.46 | 1.38 |
| MACD | -0.09 | 0.04 |
| Stochastic Oscillator | 48.74 | 84.78 |
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.